Stock Taper
SCREENER COMPARE ANY 2 STOCKS
SION
SIONNA THERAPEUTICS, INC.
NASDAQ
$5.87
▼ DOWN 3.14% (-0.19)

KEY STATISTICS

Market Cap$265.03 M
52w High$54.97
52w Low$4.01
Dividend Yield—
Frequency—
P/E-2.69
Volume782.91K
Shares Out.45.15M

COMPANY

LEADERSHIP

Michael Cloonan
CHIEF EXECUTIVE
Michael Cloonan

COMPENSATION 2026

Salary$646,580
Stock Awards$0
Incentive Plan Pay$374,062
All Other Comp.$10,000
Total$6,981,217

ABOUT

SECTOR
Healthcare
WENT PUBLIC
February 7, 2025
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
59

PRICE TARGET

Target High$60.00
Target Low$5.00
Target Median$7.00
Target Consensus$27.20

UPCOMING EARNINGS

DateNov 4, 2026
DayWednesday
Rev. Est.—
NOV
4
WED

PRICE

$5.87 ▼ DOWN 3.14% (−$0.19)
$5.85$5.92$6.00$6.089:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM5.87

About Sionna Therapeutics, Inc.

https://www.sionnatx.com ↗

Sionna Therapeutics, Inc. is a biopharmaceutical company. The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator.

INDUSTRY

Biotechnology

A PRODUCT SIONNA THERAPEUTICS, INC. IS KNOWN FOR

SION-719
SION-719

SION-719 is a first-in-class small molecule in Phase 2a trials, designed to stabilize CFTR's NBD1, serving as a potential add-on therapy for cystic fibrosis patients.

COMPETITORS

COMPETITOR
ABBV COMPARE
GILD COMPARE
KRYS COMPARE
PTCT COMPARE
VRTX COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
102
LISTED HERE
19
RANKED BY POSITION SIZE
VTI
0.00% · 934.6K
XBI
0.04% · 690.8K
IWM
0.00% · 477.6K
SCHA
0.00% · 69.3K
SBIO
0.14% · 55.6K
LABU
0.02% · 25.1K
XRSU.L
0.00% · 16.9K
FESM
0.00% · 14.0K
GSSC
0.01% · 11.5K
DFAU
0.00% · 11.5K
RSSL
0.00% · 8.8K
BBC
0.10% · 8.7K
BBSC
0.00% · 5.5K
IBBQ
0.02% · 2.8K
BIB
0.01% · 1.6K
VETS
0.05% · 338
KBFR
0.01% · 122
RESM
0.01% · 51
ESSC
0.00% · 12

INSTITUTIONAL OWNERSHIP

SHARES OWNED
85.14%
HOLDERS
130
TOP 12 OF 130 · RANKED BY POSITION SIZE
Ra Capital Management, L.P.
10.4M sh · $307.2M
Tpg Gp A, LLC
6.7M sh · $198.37M
Orbimed Advisors LLC
3.7M sh · $108.96M
Atlas Venture Life Science Advisors, LLC
3.6M sh · $106.33M
Viking Global Investors LP
3.2M sh · $128.09M
Enavate Sciences Gp, LLC
2.5M sh · $99.34M
Jpmorgan Chase & Co
2.0M sh · $58.19M
Jennison Associates LLC
1.5M sh · $58.18M
Blackrock, Inc.
1.3M sh · $51.95M
Vanguard Group Inc
1.2M sh · $48.75M
Perceptive Advisors LLC
1.2M sh · $34.68M
Citadel Advisors LLC
1.2M sh · $46.78M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
DIRECTOR
ORBIMED ADVISORS LLC
Sale · 85.9K shares
2026-07-07
★
DIRECTOR
Thompson Peter A.
Sale · 85.9K shares
2026-07-07
★
OFFICER: CHIEF LEGAL OFFICER
Fitzpatrick Jennifer
Sale · 10.3K shares
2026-07-06
★
OFFICER: CHIEF LEGAL OFFICER
Fitzpatrick Jennifer
Purchase · 10.3K shares
2026-07-06

MOST RECENT ANALYST GRADES

GRADE SUMMARY
NEUTRAL 3
BUY 2
MARKET OUTPERFORM 1
HOLD 1
UNDERPERFORM 1
8 GRADES IN THE LAST 12 MONTHS
Guggenheim NEUTRAL Wedbush NEUTRAL BTIG NEUTRAL Citizens MARKET OUTPERFORM Freedom Broker HOLD Stifel BUY Jones Trading BUY RBC Capital UNDERPERFORM

SECTORS PEERS

PEERPRICE
ABCL$11.35COMPARE
IMNM$27.57COMPARE
CLDX$39.12COMPARE
VERA$34.19COMPARE
BHVN$15.41COMPARE
ZYME$28.27COMPARE
MAZE$27.44COMPARE
XERS$8.48COMPARE